BPC-157 vs Snap-8
Side-by-side comparison of BPC-157 and Snap-8: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
BPC-157
Snap-8
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice…
Lowest listed price: $34.99 across 15 listings
Full BPC-157 profileSnap-8
Snap-8 (INCI: Acetyl Glutamyl Heptapeptide-1) is a synthetic octapeptide designed as an analog of the N-terminal fragment of synaptosomal-associated protein of 25 kDa (SNAP-25), which is the molecular target of botulinum…
Lowest listed price: $34.99 across 4 listings
Full Snap-8 profileSide-by-side comparison
| Attribute | BPC-157 | Snap-8 |
|---|---|---|
| Category | Injury, Repair & Recovery | Skin & Hair |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Nitric Oxide (NO) System Modulation BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a… | Snap-8 (INCI Acetyl Octapeptide-3; CAS 868844-74-0) is a synthetic octapeptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, whose sequence mimics the N-terminal domain of SNAP-25. SNAP-25, together with Syntaxin-1 and VAMP/synaptobrevin, forms the SNARE complex… |
| Half-Life | Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. | Not characterized (topical peptide) |
| Typical Dose Range | 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies | — |
| Dosing Frequency | Twice daily (AM and PM) for optimal serum levels; once daily acceptable | twice_daily |
| Administration | Subcutaneous, Oral, Intraperitoneal, Intravenous | Topical |
| Side Effects | Generally well-tolerated. Mild nausea or GI discomfort during initial use. Temporary increase in pain/inflammation at injury site (healing response). Rare: drowsiness, dizziness, mild headache. Very rare: transient changes in blood pressure. | Topical use at cosmetic concentrations is generally well tolerated. The most commonly reported effects are mild, transient local reactions such as erythema, tightness, dryness, or stinging, usually at higher concentrations or on sensitive/periocular skin.… |
| Molecular Weight | 1419.5 g/mol (average); molecular formula C62H98N16O22 | 1075.16 g/mol |
| Common Vial Sizes | 5mg, 10mg | 10 |
Price History
7 data points- OF
- BM
- Half Nattys
- LB
- Ion Peptide
- BHG Labs
Price History
3 data points- Ion Peptide
- OF
- Disguised Alpha
BPC-157: potential benefits
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
Snap-8: potential benefits
- Reduction of dynamic expression wrinkles (forehead, crow's feet, glabellar lines)
- SNARE complex interference — partial, reversible neuromuscular inhibition
- Topical alternative research model for neuromuscular relaxation without injected toxin
- Cosmetic peptide compounding research — high-purity raw powder applications
- Synergy with Argireline (Acetyl Hexapeptide-3) in SNARE-targeting formulations
Frequently asked
What's the difference between BPC-157 and Snap-8?
BPC-157 is a injury, repair & recovery that nitric oxide (no) system modulation bpc-157 exerts a central integrative effect through modulation of the nitric oxide system. studies by seiwerth et al. (2022) demonstrated that…. Snap-8 is a skin & hair that snap-8 (inci acetyl octapeptide-3; cas 868844-74-0) is a synthetic octapeptide, ac-glu-glu-met-gln-arg-arg-ala-asp-nh2, whose sequence mimics the n-terminal domain of snap-25.…. The two differ in mechanism, half-life (Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. vs Not characterized (topical peptide)), and typical dose range.
Which has the longer half-life, BPC-157 or Snap-8?
BPC-157 has a half-life of Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.. Snap-8 has a half-life of Not characterized (topical peptide). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, BPC-157 or Snap-8?
Lowest listed price on BodyHackGuide: BPC-157 from $34.99, Snap-8 from $34.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack BPC-157 and Snap-8?
Stacking depends on mechanism overlap, safety profile, and goals. BPC-157 and Snap-8 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy BPC-157 or Snap-8
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.